These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 29474167)

  • 21. The expanding role of immunopharmacology: IUPHAR Review 16.
    Tiligada E; Ishii M; Riccardi C; Spedding M; Simon HU; Teixeira MM; Cuervo ML; Holgate ST; Levi-Schaffer F
    Br J Pharmacol; 2015 Sep; 172(17):4217-27. PubMed ID: 26173913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Trypsin treatment of protracted forms of nervous system lesions of parotitis etiology].
    Sichko ZhV
    Vrach Delo; 1981 May; (5):116-9. PubMed ID: 7257247
    [No Abstract]   [Full Text] [Related]  

  • 23. The need for precompetitive integrative bionetwork disease model building.
    Friend SH
    Clin Pharmacol Ther; 2010 May; 87(5):536-9. PubMed ID: 20407459
    [TBL] [Abstract][Full Text] [Related]  

  • 24. B cells in the pathophysiology of autoimmune neurological disorders: a credible therapeutic target.
    Dalakas MC
    Pharmacol Ther; 2006 Oct; 112(1):57-70. PubMed ID: 16644016
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Emerging peptide therapeutics for inflammatory autoimmune diseases.
    Briand JP; Muller S
    Curr Pharm Des; 2010; 16(9):1136-42. PubMed ID: 20030611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Jay Bradner.
    Nat Rev Drug Discov; 2017 Mar; 16(4):232-233. PubMed ID: 28356589
    [No Abstract]   [Full Text] [Related]  

  • 27. The impact of metabotropic glutamate receptors into active neurodegenerative processes: A "dark side" in the development of new symptomatic treatments for neurologic and psychiatric disorders.
    Bruno V; Caraci F; Copani A; Matrisciano F; Nicoletti F; Battaglia G
    Neuropharmacology; 2017 Mar; 115():180-192. PubMed ID: 27140693
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Microglia--a therapeutic target in neurological diseases and disorders.
    Kaur C; Ling EA
    CNS Neurol Disord Drug Targets; 2013 Sep; 12(6):719. PubMed ID: 24047518
    [No Abstract]   [Full Text] [Related]  

  • 29. The immunoproteasome: a novel drug target for autoimmune diseases.
    Basler M; Mundt S; Bitzer A; Schmidt C; Groettrup M
    Clin Exp Rheumatol; 2015; 33(4 Suppl 92):S74-9. PubMed ID: 26458097
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemistry-enabled drug delivery (prodrugs): recent progress and challenges.
    Clas SD; Sanchez RI; Nofsinger R
    Drug Discov Today; 2014 Jan; 19(1):79-87. PubMed ID: 23993918
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genomics drugs in clinical trials.
    Hall J; Dennler P; Haller S; Pratsinis A; Säuberli K; Towbin H; Walther K; Woytschak J
    Nat Rev Drug Discov; 2010 Dec; 9(12):988. PubMed ID: 21119735
    [No Abstract]   [Full Text] [Related]  

  • 32. Different targets of anti-glucocorticoid treatment have been proposed, acting at supra-hypothalamic, HPA axis, glucocorticoid receptor and post-receptor levels.
    Di Marzo V
    Recent Pat CNS Drug Discov; 2013 Apr; 8(1):1. PubMed ID: 23565885
    [No Abstract]   [Full Text] [Related]  

  • 33. [Innovative approach for drug discovery by targeted therapy].
    Kikuchi H; Kato K
    Yakugaku Zasshi; 2013; 133(1):41-2. PubMed ID: 23292018
    [No Abstract]   [Full Text] [Related]  

  • 34. Heteroreceptor Complexes and their Allosteric Receptor-Receptor Interactions as a Novel Biological Principle for Integration of Communication in the CNS: Targets for Drug Development.
    Fuxe K; Borroto-Escuela DO
    Neuropsychopharmacology; 2016 Jan; 41(1):380-2. PubMed ID: 26657959
    [No Abstract]   [Full Text] [Related]  

  • 35. A network view of disease and compound screening.
    Schadt EE; Friend SH; Shaywitz DA
    Nat Rev Drug Discov; 2009 Apr; 8(4):286-95. PubMed ID: 19337271
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preclinical Medication Development: New Targets and New Drugs.
    Kasten CR; Boehm SL
    Alcohol Clin Exp Res; 2016 Jul; 40(7):1418-24. PubMed ID: 27177689
    [No Abstract]   [Full Text] [Related]  

  • 37. Targeting autoimmunity: strategies and tactics.
    Masuda ES; Payan DG
    Drug Discov Today; 2014 Aug; 19(8):1193-4. PubMed ID: 24886764
    [No Abstract]   [Full Text] [Related]  

  • 38. Accelerating Drug Development: Antiviral Therapies for Emerging Viruses as a Model.
    Everts M; Cihlar T; Bostwick JR; Whitley RJ
    Annu Rev Pharmacol Toxicol; 2017 Jan; 57():155-169. PubMed ID: 27483339
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of cyclosporine in neurological autoimmune disease?
    Johnson KP; Belendiuk G
    Arch Neurol; 1985 Nov; 42(11):1043-4. PubMed ID: 4051831
    [No Abstract]   [Full Text] [Related]  

  • 40. Tacrolimus: An updated review on delivering strategies for multifarious diseases.
    Dheer D; Jyoti ; Gupta PN; Shankar R
    Eur J Pharm Sci; 2018 Mar; 114():217-227. PubMed ID: 29277665
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.